AMRN: התחייבויות שוטפות של החברה Amarin Corporation

Amarin Corporation plc (AMRN) specializes in developing therapies for cardiovascular pathologies. This daily price chart illustrates the asset's performance, with a value of 0.00. The business implements software algorithms during drug development, although final trials require medical supervision. The company is currently experiencing stagnation due to the loss of exclusive rights to Vascepa, focusing its R&D on testing new compound combinations.

This indicator measures total liabilities with maturities of up to twelve months, determining the business's liquid stability. By analyzing short-term financial borrowings, an investor assesses the default risk and the degree of dependence on external refinancing. For Amarin Corporation plc (AMRN), this is critical during the expansion of cardiovascular drugs in Europe. Minimal debt reduces vulnerability to generics in the US. A low debt load guarantees capital preservation.